Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes
Javier Morales, MD, FACP, FACE; David Robertson, MD; Andrea Stallings, PA, and Shira Eytan, MD, FACE, examine the comprehensive burden of Type 1 diabetes, from screening guidelines and disease staging to the critical importance of early intervention, emphasizing how delayed treatment in Stage 2 can lead to severe complications and diminished therapeutic opportunities.
EP. 1: Assessing the Burden of Type 1 Diabetes
December 19th 2024Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.
EP. 2: Guidelines for Type 1 Diabetes Screening
December 23rd 2024Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.
EP. 3: Defining the Stages of Type 1 Diabetes
December 23rd 2024Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.
EP. 4: Impact of Delayed Intervention In Stage 2 Type 1 Diabetes
December 23rd 2024Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.
